Table 6 Inhibitors of Dvls
From: Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Compound | IC50 | Development stage | Ref. |
|---|---|---|---|
3289–8625 | 12.5 μM | Preclinical | [429] |
BMD4702 | ND | Preclinical | [430] |
FJ9 | ND | Preclinical | [431] |
J01-017a | 1.5 ± 0.2 μM | Preclinical | [432] |
KY-02061 | 24 μM | Preclinical | [433] |
KY-02327 | 3.1 μM | Preclinical | [433] |
NSC668036 | ND | Preclinical | [434] |
Sulindac | ND | FDA-approved nonsteroidal anti-inflammatory drug; Phase I (NCT00245024): Breast cancer; Phase II (NCT00039520): Breast cancer; Phase III (NCT01349881): Colorectal neoplasms | [426] |